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Abstract
Background: To evaluate the efficacy of diode laser photocoagulation in patients with central serous
retinopathy (CSR) and to compare it with the effects of argon green laser.
Methods: Thirty patients with type 1 unilateral CSR were enrolled and evaluated on parameters like best
corrected visual acuity (BCVA), direct and indirect ophthalmoscopy, amsler grid for recording scotoma
and metamorphopsia, contrast sensitivity using Cambridge low contrast gratings and fluorescein
angiography to determine the site of leakage.
Patients were randomly assigned into 2 groups according to the statistical random table using sequence
generation. In Group 1 (n = 15), diode laser (810 nm) photocoagulation was performed at the site of
leakage while in Group 2 (n = 15), eyes were treated with argon green laser (514 nm) using the same laser
parameters. Patients were followed up at 4, 8 and 12 weeks after laser.
Results: The mean BCVA in group 1 improved from a pre-laser decimal value of 0.29 ± 0.14 to 0.84 ±
0.23 at 4 weeks and 1.06 ± 0.09 at 12 weeks following laser. In group 2, the same improved from 0.32 ±
0.16 to 0.67 ± 0.18 at 4 weeks and 0.98 ± 0.14 at 12 weeks following laser. The improvement in BCVA
was significantly better in group 1 (p < 0.0001) at 4 weeks. At 4 weeks following laser, all the patients in
group1 were free of scotoma while 6 patients in group 2 had residual scotoma (p < 0.05). The mean
contrast sensitivity in group 1 improved from pre-laser value of 98.4 ± 24.77 to 231.33 ± 48.97 at 4 weeks
and 306.00 ± 46.57 at 12 weeks following laser. In group 2, the same improved from 130.66 ± 31.95 to
190.66 ± 23.44 at 4 weeks and 215.33 ± 23.25 at 12 weeks. On comparative evaluation, a significantly
better (p < 0.001) improvement was noted in group 1.
Conclusion: Diode laser may be a better alternative to argon green laser whenever laser treatment
becomes indicated in patients with central serous retinopathy in terms of faster visual rehabilitation and
better contrast sensitivity. In addition, diode laser also has the well-recognized ergonomic and economic
advantages.
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Background
Central serous retinopathy (CSR) is a retinal disorder
affecting young adults, characterized clinically by a well-
defined, translucent, circumscribed detachment of neuro-
sensory retina at the posterior pole, usually involving the
macula. The detachment results from accumulation of
transparent fluid in the potential space between retinal
pigment epithelial layer and the neurosensory retina.
However, the source of this fluid and the exact etiopatho-
genesis of this disorder remain ill understood. Maumenee
[1] described the concept of leakage site within the retinal
pigment epithelial layer following fluorescein angio-
graphic studies in patients with central serous retinopa-
thy. Recent studies [2-4], using indocyanine green
angiography, have indicated that the possible site of pri-
mary pathology in central serous retinopathy is the
choroidal vessels and the involvement of the pigment epi-
thelial layer is only secondary to it.
Although, other treatment modalities have been sug-
gested for central serous retinopathy, argon green (514
nm) laser photocoagulation has been the most widely
accepted modality. The 810 nm-diode laser owing to
deeper penetration should prove to be more efficacious in
the treatment of central serous retinopathy given the cur-
rent thinking that CSR may primarily be a choroidal dis-
ease. The present study was undertaken to test the efficacy
of diode laser photocoagulation in central serous retinop-
athy in comparison to argon green laser. According to the
best of our knowledge, this is the first clinical study in
which a comparative evaluation between the above two
groups has been done in central serous retinopathy.
Methods
Thirty patients of unilateral central serous retinopathy
presenting to the retina services at the Rajendra Prasad
Centre for Ophthalmic Sciences were selected for the
study. They were randomly assigned into 2 groups accord-
ing to the statistical random table using sequence genera-
tion. As it was a pilot study we decided only the
convenient sample size i.e. 15 in each group. The alloca-
tion of patients into 2 groups was done by a person who
was not involved in the study and the sequence was con-
cealed until interventions were assigned to prevent bias.
The patient selection was based on the following inclu-
sion criteria: age less than 50 years, type 1 CSR with a sin-
gle leak on fluorescein angiography that was at least 300
microns away from fovea, presence of an indication for
laser treatment (recurrence, occupational, history of poor
visual outcome in fellow eye) and no history of any treat-
ment in the past. Patients with multiple leak CSR, type 2
or type 3 CSR or leak at papillomacular bundle or leak
within 300 µ from the foveal centre were not included in
the study. Patients with other ocular pathology such as
choroidal neovascularization, choroidal inflammatory or
neoplastic disorder or a congenital optic nerve pit were
also excluded from the study.
Informed consent was obtained from all the patients
included in the study before initiating treatment and an
approval of the institute body ethics committee was
obtained to undertake the study. In all the patients the fol-
lowing parameters were evaluated before laser treatment
and also during the follow-up period: best corrected visual
acuity (BCVA) on Snellen's acuity chart, fundus examina-
tion by direct and indirect ophthalmoscopy, amsler grid
for determining the degree of scotoma and / or metamor-
phopsia, contrast sensitivity using Cambridge low con-
trast gratings and fluorescein angiography (Canon CF-60
UD camera using 400ASA, 35-mm black and white film).
Technique of scoring scotoma and metamorphopsia on
the amsler grid is described below:
The amsler grid consists of a 10-cm square divided into
smaller 5 mm squares. When it is viewed at one-third of a
meter, each small square subtends an angle of 1°. The
patient was asked to look directly at the central spot with
the uncovered eye and to mark out any black spot, distor-
tion of lines, or blurred area on the grid. The number of
small squares within the area delineated by the patient
was counted and scotoma and metamorphopsia score was
graded numerically as shown in table 1 and 2.
Table 1: Amsler Grid: Scotoma Score
No of small squares Grade
00
1 – 50 I
51 – 100 II
101 – 150 III
151 – 200 IVBMC Ophthalmology 2004, 4:15 http://www.biomedcentral.com/1471-2415/4/15
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Patients included in the study were randomly assigned to
one of the following two groups. In group 1 (n = 15), the
site of leakage was treated by diode laser (810 nm). Laser
was performed with Volk area centralis contact lens
(Keeler Ltd, Clewer Hill Road, Windsor, Berks, SL4 4AA)
and the parameters used were spot size of 100 microns,
duration of 100 to 200 milliseconds and power just
enough to produce minimal greying. In group 2 (n = 15),
patients were treated with argon green laser (514 nm) fol-
lowing the same laser parameters. Patients were followed
up at intervals of 4, 8 and 12 weeks after laser treatment
and the results were analyzed, which included a compar-
ative analysis of the outcome between the two groups.
Descriptive statistics i.e. mean and standard deviation was
calculated for each variable at each follow-up for the 2
groups. To see the significant difference between the 2
groups at each point we applied "student 't' test"
(unpaired). To see the trend within the group we applied
"two way analysis of variance (ANOVA)". 'P' value of 0.05
was considered as statistically significant. BMDP 7.0 sta-
tistical package was used for the statistical analysis.
Results
The average age of the patients in group 1 was 34.06 ±
2.54 years (range: 30–40 years) and in group 2, it was
34.66 ± 3.23 years (range: 30–42 years). Twelve cases
(80%) in group 1 and 13 patients (86.66%) in group 2
were males. All the patients presented to us within eight
days (range: 3–8 days) of onset of visual symptoms. The
average number of laser spots applied to the leakage site
in group 1 was 3.13 ± 0.71 (range: 2–4) and in group 2 it
was 3.26 ± 0.77 (range: 2–4). All the patients came regu-
larly for the follow-up as per the protocol during entire
period of study. The study was performed during the
period between January 1998 and June 2000.
The mean best-corrected visual acuity (BCVA) in decimal
at the time of presentation in patients assigned to group 1
was 0.29 ± 0.14. Best corrected visual acuity four weeks
after diode laser treatment had improved to 0.84 ± 0.23.
The BCVA further improved to 0.97 ± 0.17 and 1.06 ±
0.09 at 8 weeks and 12 weeks respectively. In group 2, the
mean BCVA at the time of presentation was 0.32 ± 0.16
and it improved to 0.67 ± 0.18 at 4 weeks follow-up after
argon green laser photocoagulation. Further improve-
ment in visual acuity to 0.91 ± 0.19 and 0.98 ± 0.14 at 8
weeks and 12 weeks follow up respectively was observed.
Statistical analysis of data pertaining to improvement of
BCVA in the two groups by student 't' test, showed a sta-
tistically significant difference at 4 weeks with patients
treated by diode laser (group 1) having a better improve-
ment (p < 0.001) (Figure 1). This difference decreased and
was not found to be statistically significant during later
follow-up at 8 and 12 weeks.
All the patients in both the groups had central scotoma at
the time of presentation. At the first follow up at 4 weeks
following laser treatment, all the patients in group 1 (n =
15) were free of scotoma while 6 patients in group 2 (n =
15) had residual scotoma of grade 1 (involving 1–50
small squares on the amsler grid). On comparative evalu-
ation, this difference was found to be statistically signifi-
cant (p < 0.05). At 8 weeks and 12 weeks follow up, none
of the patients had residual scotoma; however, 3 patients
in group 2 developed a paracentral scotoma correspond-
ing to the site of laser scar.
Four patients in group 1 and five in group 2 had com-
plaints of metamorphopsia at the time of presentation. At
the first follow up at 4 weeks, 2 cases in group 1 and 4
cases in group 2 were still having grade 1 metamorphop-
sia. On comparative evaluation, this difference in the two
groups was not found to be significant statistically. At 8
weeks and 12 weeks follow up, all patients in both the
groups were free of metamorphopsia.
Contrast sensitivity was evaluated using the Cambridge
low contrast gratings. The reference normal for our
patients as observed in earlier studies at our centre has
been 340 (range 310–370) (unpublished data). The mean
absolute value of contrast sensitivity at the time of presen-
tation in group 1 was 98.4 ± 24.77. This improved to
231.33 ± 48.97 at the first follow up at 4 weeks following
diode laser photocoagulation. It further improved to
286.00 ± 48.52 at 8 weeks follow up and 306.00 ± 46.57
at the third follow up at 12 weeks. In group 2, the mean
Table 2: Amsler Grid: Metamorphopsia Score
No of small squares Grade
00
1 – 25 I
26 – 50 II
51 – 75 III
76 – 100 IVBMC Ophthalmology 2004, 4:15 http://www.biomedcentral.com/1471-2415/4/15
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value of contrast sensitivity at the time of presentation was
130.66 ± 31.95, which improved to 190.66 ± 23.44 at 4
weeks following argon green laser treatment. This value
further improved to 210.00 ± 27.25 at 8 weeks and 215.33
± 23.25 at 12 weeks follow up. Comparative evaluation of
the improvement in contrast sensitivity by student 't' test
between the two groups showed that there was an initial
rapid improvement in contrast sensitivity in both the
groups but group I patients had a significantly greater
improvement than group 2 patients at all the follow up
visits (p < 0.001) (Figure 2).
In both the groups, the commonest site of fluorescein
leakage was the area superonasal to fovea. Fluorescein
angiography repeated 4 weeks later showed that in both
the groups, all the patients had complete resolution of the
leakage site. No recurrence was reported till completion of
follow up at 12 weeks.
Discussion
Visual prognosis in central serous retinopathy in most
cases is good as they resolve spontaneously. Klein M et al.
[5] studied and followed up 34 eyes of CSR without giving
any treatment and found that final visual acuity was 20/
30 or better. The average time for the fluid to resolve was
between 3 months to 6 months and there was a recurrence
rate of 45%. Sequelae such as macular degeneration and
chronic retinal pigment epithelial decompensation are
rare after the first episode. However, in a small group of
patients visual prognosis has been reported to be less
favorable [6,7].
Encouraging results of laser photocoagulation has been
found in various studies which conclude that laser
photocoagulation could effectively decrease the time for
visual recovery in patients with central serous retinopathy
[8-10]. However, the ultimate visual acuity despite laser
photocoagulation remained no different from patients in
whom no treatment was done and that recurrences could
not be prevented by laser photocoagulation [10].
Results of treatment of the leakage site in patients with
central serous retinopathy with ruby [9], krypton [11,12]
and argon lasers [9,10,13,14] and Xenon arc [15] have
been reported in the literature. Although, Slusher [11]
suggested that the wavelength emitted by krypton laser
Best Corrected Visual Acuity – Group 1 (Diode) Vs Group 2 (Argon green) Figure 1
Best Corrected Visual Acuity – Group 1 (Diode) Vs Group 2 (Argon green)
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might be more tissue-selective, argon green laser
photocoagulation has been the most widely accepted
treatment modality in patients with central serous retin-
opathy [9,10,12-14].
Studies performed with indocyanine green angiography
in cases of central serous retinopathy have reported that
hyperpermeability of choroidal vessels could be the pri-
mary pathology in CSR and retinal pigment epithelial
abnormality is only secondary to it [2-4].
Brancato R et al [16] performed transpupillary chorioreti-
nal photocoagulation in rabbit eyes using a diode laser
prototype and a commercially available argon laser and
found that they were similar on ophthalmoscopy. How-
ever, histopathological examination performed twenty-
four hours after the treatment showed that argon irradia-
tion resulted in damage to both the inner and outer retinal
layers while the diode laser radiation produced damage to
outer retina and choroid. If this were true, energy deliv-
ered by argon laser (514 nm) seems inadequate in being
able to reach the deeper choroidal layers and treat the pri-
mary site of pathology. This inherent limitation of argon
laser in view of recent ICG reports on the pathogenesis of
central serous retinopathy could also explain the less than
ideal outcome in the earlier studies using this laser in the
treatment of patients with central serous retinopathy. The
810 nm-diode laser emission is in the near infrared (810
nm) region and this wavelength is able to reach the deeper
choroidal layers [16-18]. Hence, we felt that the 810 nm-
diode laser may theoretically be more efficacious in the
laser treatment of central serous retinopathy.
Our observations showed that following diode laser treat-
ment in patients with central serous retinopathy, the
recovery of visual acuity was more rapid in comparison to
Contrast Sensitivity – Group 1 (Diode) Vs Group 2 (Argon green) Figure 2
Contrast Sensitivity – Group 1 (Diode) Vs Group 2 (Argon green)
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the argon laser treatment group. Further, all the patients
treated with diode laser showed complete resolution of
scotoma at the first follow up at 4 weeks and none of them
developed a scotoma corresponding to the site of laser
treatment. In contrast, in patients subjected to argon green
laser treatment, there was a significant residual scotoma at
4 weeks and 20% of the patients developed scotoma cor-
responding to the laser scar.
Following laser treatment, contrast sensitivity in both the
groups improved rapidly in the first four weeks. However,
there was significantly greater improvement in contrast
sensitivity in eyes subjected to diode laser. This observa-
tion is indicative that diode laser is more beneficial with
regard to conservation of contrast sensitivity following
laser treatment in patients with central serous retinopathy.
Development of subretinal neovascularization following
laser treatment for central serous retinopathy has been
described earlier in literature [19]. However, in our study
none of the patients in any group developed this
complication.
The present study suggests that diode laser photocoagula-
tion brings about a faster quantitative and qualitative vis-
ual recovery in comparison to argon green laser in eyes
with central serous retinopathy. The main aim of perform-
ing laser photocoagulation in eyes with CSR is to hasten
resolution and this is better fulfilled by diode laser. Fur-
ther, as argon laser can hit up to the outer retinal layers, it
can seal the site of leaking retinal pigment epithelium, but
it cannot reduce the fluid overload over the pigment epi-
thelial layer caused by hyperpermeability of choriocapil-
laries, which can be the cause of recurrence of CSR. As
diode laser hits the choroid, which is the exact site of
pathology, it should reduce the fluid overload on the ret-
inal pigment epithelium.
Conclusions
In the present study, our observations are suggestive that
diode laser may be a better alternative to argon laser
whenever laser treatment is indicated in patients with cen-
tral serous retinopathy. In addition, diode laser also has
the well-recognized economic and ergonomic advantages
of being less costly, more efficient, portable and easy to
maintain [20,21], which is also a matter of concern partic-
ularly in third world countries.
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